Fei‐Ting Hsu
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetics top 5%
- Glioma Diagnosis and Treatment
Papers in
- Hepatology 22
- Hepatocellular Carcinoma Treatment and Prognosis 22
-
- Magnolia and Illicium research 15
- Co-authors
- Yu‐Chang Liu (25 shared papers)I‐Tsang Chiang (28 shared papers)Jing‐Gung Chung (20 shared papers)Jeng‐Jong Hwang (12 shared papers)Song‐Shei Lin (13 shared papers)Po–Jung Pan (6 shared papers)Cheng‐Yu Chen (10 shared papers)Jiann‐Hwa Chen (8 shared papers)
- Journals
- Anticancer Research (25 papers)Biomedicine & Pharmacotherapy (7 papers)Environmental Toxicology (6 papers)International Journal of Molecular Sciences (5 papers)Journal of Cellular and Molecular Medicine (4 papers)
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Fei‐Ting Hsu
115 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 88
- Hepatology 252
- Genetics 191
- Rehabilitation 138
- Biomaterials 186
- Drug Discovery 4
Countries citing papers authored by Fei‐Ting Hsu
This map shows the geographic impact of Fei‐Ting Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei‐Ting Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei‐Ting Hsu more than expected).
Fields of papers citing papers by Fei‐Ting Hsu
This network shows the impact of papers produced by Fei‐Ting Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei‐Ting Hsu. The network helps show where Fei‐Ting Hsu may publish in the future.
Co-authors
The 25 scholars most cited alongside Fei‐Ting Hsu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 239 | |
| 2 | 2022 | 84 | |
| 3 | 2016 | 57 | |
| 4 | Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells. | 2013 | 54 |
| 5 | 2016 | 54 | |
| 6 | 2014 | 53 | |
| 7 | 2016 | 44 | |
| 8 | 2019 | 44 | |
| 9 | 2018 | 41 | |
| 10 | 2020 | 41 | |
| 11 | 2010 | 38 | |
| 12 | 2020 | 38 | |
| 13 | 2015 | 36 | |
| 14 | 2019 | 36 | |
| 15 | 2014 | 34 | |
| 16 | 2019 | 34 | |
| 17 | 2018 | 33 | |
| 18 | 2019 | 33 | |
| 19 | 2020 | 33 | |
| 20 | 2017 | 32 |
About Fei‐Ting Hsu
Fei‐Ting Hsu is a scholar working on Hepatology, Rehabilitation, Pharmacology, Genetics and Cancer Research, having authored 121 papers that have together received 2.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Flavonoids in Medical Research (17 papers), Magnolia and Illicium research (15 papers), Glioma Diagnosis and Treatment (12 papers), Cancer, Stress, Anesthesia, and Immune Response (7 papers), Sarcoma Diagnosis and Treatment (6 papers), NF-κB Signaling Pathways (6 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Hepatology (252 citations), Genetics (191 citations), Rehabilitation (138 citations), Biomaterials (186 citations) and Drug Discovery (4 citations). Fei‐Ting Hsu has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Yu‐Chang Liu, I‐Tsang Chiang, Jing‐Gung Chung, Jeng‐Jong Hwang, Song‐Shei Lin, Po–Jung Pan, Cheng‐Yu Chen, Jiann‐Hwa Chen, Ping‐Huei Tsai and Yu‐Chieh Jill Kao. Their work appears in journals such as Anticancer Research, Biomedicine & Pharmacotherapy, Environmental Toxicology, International Journal of Molecular Sciences and Journal of Cellular and Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.